AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02588729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnant+ app for smartphone
Description: The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
Study NCT04798326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW032
Description: Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.
Study NCT04798326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.
Study NCT03351153 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: X-ray
Description: In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week
Study NCT03351153 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CT
Description: In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week
Study NCT03351153 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: specimen
Description: In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
Study NCT01515566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
Study NCT01515566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9% preservative free SQ 15 minutes before walk test.
Study NCT01515566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Tests
Description: 6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
Study NCT01515566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking Tests
Description: 6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
Study NCT01515566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
Study NCT01515566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
Study NCT00481013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid (VPA)
Description: Drug: Valproic Acid and Levocarnitine; capsules
Study NCT00481013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
Study NCT05111938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friends, Family, and Food App (F3A-App)
Study NCT03584425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rasch modified version of the Fugl-Meyer Motor assessment
Description: All participants will receive a comprehensive clinical assessment of motor function including the Rasch modified version of the Fugl-Meyer Motor assessment and a kinematic assessment of unimanual and bimanual movements using a 45 sensor 3D active marker based motion capture system. The three primary measures investigated in the kinematics include: 1) movement efficiency, 2) movement smoothness, and 3) motor compensation.
Study NCT03584425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anatomical image acquisition
Description: High-resolution structural scans will be obtained using an inversion recovery 3D spoiled gradient echo (3DSPGR) sequence using a matrix size of 256 x 256, field of view of 24 cm, section thickness of 1.5 mm with no gap between sections, and 128 slices, giving an in-plane resolution of 0.94 mm. This sequence will be used for anatomic overlays of the functional data and for spatial normalization to a standard atlas.
Study NCT03584425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI task and acquisition
Description: Briefly, patients will be given two pressure-sensitive bulbs (one to be held in each hand and fastened lightly to their wrists with Velcro such that they do not drop it during the scan. During two 2½ minute runs they will be prompted to squeeze the bulb in either their affected or unaffected hand in blocks of 15 seconds. These blocks will be interspersed with blocks of rest. The pressure from the bulbs will be digitally recorded and quantified offline in order to: 1) verify that the patient was squeezing the ball, and 2) assess the presence of 'mirror movements' from the opposing hand that may inform the imaging results regarding loss of laterality).
Study NCT03363308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training for health care workers supplmented by QI teams
Description: Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
Study NCT00670657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
Study NCT00634686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA/EPA
Description: 1.2 gram capsule daily for 6 months
Study NCT00634686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: daily for 6 months
Study NCT00634686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium with vitamin D
Description: 1000 mg of calcium with 1000 IU vitamin D daily for 6 months
Study NCT00634686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium with vitamin D
Description: 1000 mg of calcium with 1000 IU vitamin D daily for 6 months
Study NCT02126124 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
Study NCT02126124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active dTMS Treatment
Description: Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
Study NCT01841034 — intervention group
Intervention type: DRUG
Intervention: Conceptio EA
Description: The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
Study NCT00802958 — intervention group
Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Ointment-Reference Product
Description: Small amount applied and evaluated over the course of a day
Study NCT00802958 — intervention group
Intervention type: DRUG
Intervention: Halobetasol Propionate 0.05% Ointment-Test Product
Description: Small amount applied and evaluated over the course of a day
Study NCT01908582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT01908582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Administered orally
Study NCT03409484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concord Grape Juice
Description: Concord Grape Juice
Study NCT03409484 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low flavoniod low essence beverage
Description: Low flavoniod low essence beverage
Study NCT03409484 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low flavonoid beverage
Description: Low flavonoid beverage
Study NCT03911947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrolung
Description: Device for vibroacoustic respiratory therapy
Study NCT01812616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
Study NCT01812616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Study NCT04282616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based unstructured physical activity program
Description: Counselling on physical activity according to American College of Sports Medicine guidelines
Study NCT04282616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based structured low-intensity physical activity program
Description: Structured home-based low-intensity intermittent walking program
Study NCT04282616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-hospital structured supervised physical activity program
Description: Supervised exercise training program
Study NCT02254798 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: this is a non interventional study
Study NCT02760121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Study NCT02760121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide
Study NCT02760121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04318262 — intervention group
Intervention type: BIOLOGICAL
Intervention: Determination of the clinical and biological characteristics
Description: * clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis...), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications...~* biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP...
Study NCT04318262 — intervention group
Intervention type: BIOLOGICAL
Intervention: Description of the antibiotic resistance profile
Description: Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
Study NCT00196391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021a
Description: 1 capsule daily for 10 days
Study NCT00196391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021b
Description: 1 capsule daily for 10 days
Study NCT04318262 — intervention group
Intervention type: BIOLOGICAL
Intervention: Molecular epidemiology of S. lugdunensis infections
Description: Genome sequencing (Illumina technique)
Study NCT01734083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise
Description: The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
Study NCT01734083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
Study NCT01734083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional exercise
Description: The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
Study NCT00888290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
Study NCT00888290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo at 3 different doses to match Sodium bicarbonate dosing
Study NCT00073645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer/Group CBT
Description: Children will be trained to be more helpful and positive toward other children through role-playing activities.
Study NCT00073645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family/Parents CBT
Description: Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
Study NCT00196391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021c
Description: 1 capsule daily for 10 days
Study NCT00196391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021d
Description: 1 capsule daily for 10 days
Study NCT00196391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021e
Description: 1 capsule daily for 10 days
Study NCT00196391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 matching placebo capsule for 10 days
Study NCT00064142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: halofuginone hydrobromide
Description: Applied topically
Study NCT00064142 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied topically
Study NCT00064142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00064142 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00064142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00064142 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT04211077 — intervention group
Intervention type: OTHER
Intervention: Date collection
Description: Data collection from national SNIIRAM and PMSI database
Study NCT00304772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 400mg/day
Study NCT00304772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: 150mg/day
Study NCT04250753 — intervention group
Intervention type: OTHER
Intervention: Walking task
Description: 30 meters walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30 meters walking task twice. Inertial sensors are put on each participant foot.
Study NCT01658020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabofloxacin
Description: Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
Study NCT01658020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg tablet P.O. once daily for 7days
Study NCT04337671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training
Description: The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively.~Frequency: 3 sessions/week , and Duration:12 weeks.
Study NCT03013140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid therapy
Description: Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV\<5%
Study NCT03013140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Description: Inject marcaine and fentanyl to CSF for anaesthesia
Study NCT03013140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anaesthesia
Description: Inject marcaine and fentanyl to CSF for anaesthesia
Study NCT02482610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
Study NCT02482610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Whole Fat Milk
Description: Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
Study NCT02482610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Non-fat Milk
Description: Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
Study NCT01126697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 and Lisinopril
Description: Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
Study NCT01495910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
Study NCT04507633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROMA therapy(reminiacence therpy, orientation, music, and art)
Description: An intervention comprising reminiscence of annual festivals, orientation, and familiar music listening and singing, and animation interaction to improve cognitive functions, depressive symptoms and behaviors problems.
Study NCT04355936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
Description: Control arm will receive standard care.
Study NCT04886752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: vitamin C without liposome
Description: subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
Study NCT01338376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Education
Description: All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.~* Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS~* Physician Activity: frequent insulin titration
Study NCT01338376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diabetes Education
Description: The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.~* Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia~* Physician Activity: less frequent insulin titration
Study NCT01338376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scilin®M30
Description: Subjects will be treated with Scilin®M30 twice daily
Study NCT01338376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scilin®M30
Description: Subjects will be treated with Scilin®M30 twice daily
Study NCT04886752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: liposomal process A vitamin C
Description: subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
Study NCT04886752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: liposomal process B vitamin C (Double Nutri™)
Description: subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start